Renal Blood Flow as Marker for Disease Progression in ADPKD.
- 1Division of Nephrology, Department of Internal Medicine, University Medical Cencer Groningen, University of Groningen, Groningen, The Netherlands.
- 2Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
Background
Disease progression in autosomal dominant polycystic kidney disease (ADPKD) is variable. Renal blood flow (RBF) and filtration fraction (FF), reflecting hemodynamic alterations and hyperfiltration, may improve risk stratification.Methods
This prospective study included 238 adults with ADPKD from the Developing Intervention Strategies to Halt Progression of ADPKD observational cohort study and 1421 healthy controls. Multivariable regression analyses assessed associations of RBF and FF with disease severity and progression. Kaplan-Meier analysis and classification performance metrics were used to evaluate clinical use beyond established risk stratification tools.Results
Cross-sectionally, patients with ADPKD had significantly lower RBF compared with controls across all age groups, even in young patients with similar estimated glomerular filtration rate (eGFR) to controls. Within patients with ADPKD, lower RBF was associated with reduced kidney function and larger kidney volume. During follow-up of 5.6 ± 3.5 years, higher RBF (per SD) was associated with slower annual eGFR decline (standardized β = 0.34; 95% confidence interval [CI], 0.09-0.58; P = 0.01), lower odds of rapid disease progression (eGFR decline ≥ 3.0 ml/min per 1.73 m²/year) (odds ratio [OR] = 0.34; 95% CI, 0.17-0.70; P = 0.003) and lower composite-end point risk (kidney failure or ≥ 30% eGFR decline) (hazard ratio [HR] = 0.35; 95% CI, 0.20-0.60; P < 0.001). FF was significantly higher in patients aged 30-40 years, consistent with early hyperfiltration, but was not associated with disease progression. For the association with rapid progression, adding RBF to the Mayo Imaging Classification (MIC) increased the area under the curve (AUC) from 0.69 (95% CI, 0.60-0.76) to 0.79 (95% CI, 0.72-0.85).Conclusion
Reduced RBF is an early hallmark of ADPKD, associated with disease severity and kidney function decline, and improves risk stratification beyond MIC.
Related
- Fibrogenesis Biomarkers and Clinical Disease Progression in ADPKD
- Real-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort.
- ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting
- An Exploratory Multiome Analysis of a BCG-Associated HSPC Signature: Trained-Immunity Marker in Blood and an Adverse Prognostic Association in Tumour
- Hyaluronan Synthase Isoforms Direct Distinct Patterns of Fibroblast Activation Linked to Fibrosis Progression Versus Resolution Following Renal Ischaemia
BibTeX
@article{wagenaar2026renal,
title = {{Renal Blood Flow as Marker for Disease Progression in ADPKD.}},
author = {Rijk Wagenaar and Abdulfataah A A Mohamed and Esther Meijer and Martin H De Borst and Maatje A van Gastel and Lianne A Messchendorp and Ron T Gansevoort and Thomas Bais and DIPAK consortium3 and DIPAK consortium},
journal = {Kidney international reports},
year = {2026},
month = sep,
doi = {10.1016/j.ekir.2026.107050},
url = {https://europepmc.org/article/MED/42926819},
note = {CC BY},
}
RIS
TY - JOUR
TI - Renal Blood Flow as Marker for Disease Progression in ADPKD.
AU - Rijk Wagenaar
AU - Abdulfataah A A Mohamed
AU - Esther Meijer
AU - Martin H De Borst
AU - Maatje A van Gastel
AU - Lianne A Messchendorp
AU - Ron T Gansevoort
AU - Thomas Bais
AU - DIPAK consortium3
AU - DIPAK consortium
PY - 2026
DA - 2026/09/01
JO - Kidney international reports
DO - 10.1016/j.ekir.2026.107050
UR - https://europepmc.org/article/MED/42926819
AB - Background Disease progression in autosomal dominant polycystic kidney disease (ADPKD) is variable. Renal blood flow (RBF) and filtration fraction (FF), reflecting hemodynamic alterations and hyperfiltration, may improve risk stratification.Methods This prospective study included 238 adults with ADPKD from the Developing Intervention Strategies to Halt Progression of ADPKD observational cohort study and 1421 healthy controls. Multivariable regression analyses assessed associations of RBF and FF with disease severity and progression. Kaplan-Meier analysis and classification performance metrics were used to evaluate clinical use beyond established risk stratification tools.Results Cross-sectionally, patients with ADPKD had significantly lower RBF compared with controls across all age groups, even in young patients with similar estimated glomerular filtration rate (eGFR) to controls. Within patients with ADPKD, lower RBF was associated with reduced kidney function and larger kidney volume. During follow-up of 5.6 ± 3.5 years, higher RBF (per SD) was associated with slower annual eGFR decline (standardized β = 0.34; 95% confidence interval [CI], 0.09-0.58; P = 0.01), lower odds of rapid disease progression (eGFR decline ≥ 3.0 ml/min per 1.73 m²/year) (odds ratio [OR] = 0.34; 95% CI, 0.17-0.70; P = 0.003) and lower composite-end point risk (kidney failure or ≥ 30% eGFR decline) (hazard ratio [HR] = 0.35; 95% CI, 0.20-0.60; P < 0.001). FF was significantly higher in patients aged 30-40 years, consistent with early hyperfiltration, but was not associated with disease progression. For the association with rapid progression, adding RBF to the Mayo Imaging Classification (MIC) increased the area under the curve (AUC) from 0.69 (95% CI, 0.60-0.76) to 0.79 (95% CI, 0.72-0.85).Conclusion Reduced RBF is an early hallmark of ADPKD, associated with disease severity and kidney function decline, and improves risk stratification beyond MIC.
SN - 2468-0249
ER -